ion582
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05127226)
Timeline
Indications
Studied for
Mechanism of action
- Ubiquitin-protein ligase E3AANTISENSE INHIBITOR
antisense inhibitor - UBE3A
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06914609 | Phase 3 | Jun 10, 2025 | Ionis Pharmaceuticals, Inc. |
| NCT05127226 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Ionis Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1